Enrollment Suspended In Trials Approved By Coast IRB After FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Many large and small drug firms are clients of Coast IRB, which was caught approving a fraudulent study.
You may also be interested in...
FDA IRB Crackdown Garners Praise From Former Chief Counsel Hutt
Coast IRB investigation “shook up IRBs,” Hutt says during BIO panel, “which is good.” Former Deputy Commissioner Torti, Penn’s Fitzgerald note dangers of excessive regulation of IRBs.
FDA IRB Crackdown Garners Praise From Former Chief Counsel Hutt
Coast IRB investigation “shook up IRBs,” Hutt says during BIO panel, “which is good.” Former Deputy Commissioner Torti, Penn’s Fitzgerald note dangers of excessive regulation of IRBs.
IRB Oversight: HHS’ Registration Practices, Firms Conduct To Face Greater Scrutiny
Hearing in House may boost prospects of legislation that would impose new requirements on the initial approval of clinical trials.